fda and glp 1 In a major milestone for obesity care, the has approved Wegovy® as the first oral GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight related conditions Pharmacovigilance Assessment of Compounded GLP-1
Description
We still don't know about long-term developmental impacts and the researchers themselves called for more studies on this topic
Flow cytometry permits co-detection of GLP-1R with immune markers, but the reliance on antibodies underscores the importance of rigorous reagent validation
Data Availability Statement There are no data underlying this work.
Getting the timing right matters
Discontinue the drug approximately 1 to 2 weeks prior to elective surgery for the majority of patients
Blue Cross Blue Shield sometimes covers the cost of Wegovy, but prior authorization may be required
